Literature DB >> 1549846

The significance of the anti-class I response. II. Clinical and pathologic features of renal transplants with anti-class I-like antibody.

P F Halloran1, J Schlaut, K Solez, N S Srinivasa.   

Abstract

Although the ability of preformed anti-class I antibodies to mediate hyperacute rejection is well established, their pathogenic role in acute rejection remains ill-defined. We set out to identify patients with anti-class I against donor cells and to define the clinical and pathological features of such patients. We collected sera pretransplant and in the first 3 months posttransplant from 64 renal transplant recipients (59 cadaver donors and 5 one-haplotype matched living-related donors). We assayed the sera for class I-like antibody against donor T cells in complement-dependent microcytotoxicity, with crossmatches against autologous T cells to exclude auto-antibodies. All pretransplant sera were negative against donor T cells. Of the 797 sera tested posttransplant, 131/195 sera from 13 patients were positive, and 602 sera from 51 patients were negative. All patients who formed anti-class I underwent rejections compared with only 41% of patients with no anti-class I detected (P less than 0.0005). More rejections in patients with anti-class I were classed as severe (12/15 [80%] compared with 9/28 [32%] P less than 0.005), and graft loss was significantly higher (5/13 vs. 2/51; P less than 0.002). Rejections associated with anti-class I occurred earlier; more frequently developed oliguria (35% versus 10%) and required dialysis (40% versus 10%) and biopsies (10/13 vs. 6/28); and had a higher rate of rise in serum creatinine (249 versus 79 microns/L in the first 48 hr). Biopsies during anti-class I positive rejections more frequently displayed endothelial injury in the microcirculation, neutrophils in the glomeruli and/or peritubular capillaries, and fibrin deposition in glomeruli or blood vessels. The biopsies in anti-class I negative rejection episodes tended to have tubulitis, interstitial infiltration, and blasts, suggesting that these lesions reflect T-cell-mediated mechanisms. We conclude that patients with antibody against donor class I had more severe rejection, probably because anti-class I injuries the endothelium of small blood vessels of the graft, leading to rapid functional deterioration. We believe that anti-class I may be a major factor in some severe rejection episodes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1549846

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  31 in total

Review 1.  [Alloantibodies-mediated kidney transplant rejection: a pair of continuing approaches, and with nonetheless many open questions].

Authors:  Georg Böhmig
Journal:  Wien Klin Wochenschr       Date:  2006-07       Impact factor: 1.704

2.  Antibody to human leukocyte antigen triggers endothelial exocytosis.

Authors:  Munekazu Yamakuchi; Nancy C Kirkiles-Smith; Marcella Ferlito; Scott J Cameron; Clare Bao; Karen Fox-Talbot; Barbara A Wasowska; William M Baldwin; Jordan S Pober; Charles J Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-17       Impact factor: 11.205

3.  Revisiting traditional risk factors for rejection and graft loss after kidney transplantation.

Authors:  T B Dunn; H Noreen; K Gillingham; D Maurer; O G Ozturk; T L Pruett; R A Bray; H M Gebel; A J Matas
Journal:  Am J Transplant       Date:  2011-08-03       Impact factor: 8.086

Review 4.  Antibody-mediated rejection: emergence of animal models to answer clinical questions.

Authors:  William M Baldwin; Anna Valujskikh; Robert L Fairchild
Journal:  Am J Transplant       Date:  2010-03-19       Impact factor: 8.086

5.  Reassessing the Significance of Intimal Arteritis in Kidney Transplant Biopsy Specimens.

Authors:  Israel D R Salazar; Maribel Merino López; Jessica Chang; Philip F Halloran
Journal:  J Am Soc Nephrol       Date:  2015-04-27       Impact factor: 10.121

Review 6.  Enhancing the Value of Histopathological Assessment of Allograft Biopsy Monitoring.

Authors:  Michelle A Wood-Trageser; Andrew J Lesniak; Anthony J Demetris
Journal:  Transplantation       Date:  2019-07       Impact factor: 4.939

7.  Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss.

Authors:  Denis Viglietti; Alexandre Loupy; Dewi Vernerey; Carol Bentlejewski; Clément Gosset; Olivier Aubert; Jean-Paul Duong van Huyen; Xavier Jouven; Christophe Legendre; Denis Glotz; Adriana Zeevi; Carmen Lefaucheur
Journal:  J Am Soc Nephrol       Date:  2016-08-04       Impact factor: 10.121

Review 8.  Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease.

Authors:  Juan Jesus Carrero; Manfred Hecking; Nicholas C Chesnaye; Kitty J Jager
Journal:  Nat Rev Nephrol       Date:  2018-01-22       Impact factor: 28.314

9.  Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients.

Authors:  Laurie D Snyder; Ziwei Wang; Dong-Feng Chen; Nancy L Reinsmoen; C Ashley Finlen-Copeland; W Austin Davis; David W Zaas; Scott M Palmer
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

Review 10.  The paradoxical functions of B cells and antibodies in transplantation.

Authors:  Marilia I Cascalho; Brian J Chen; Mandy Kain; Jeffrey L Platt
Journal:  J Immunol       Date:  2013-02-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.